Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.56 |
| ▸ | ERBB2 | P04626 | 13/20 | 0.55 |
| ▸ | GAK | O14976 | 1/20 | 0.52 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.51 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5061256 | 0.95 | EGFR (0.57) | EGFRERBB2GAK | |
| SCHEMBL5067525 | 0.90 | EGFR (0.66) | EGFRERBB2GAKERBB3ERBB4 | |
| SCHEMBL5064133 | 0.89 | EGFR (0.66) | EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL5067530 | 0.89 | EGFR (0.56) | EGFRERBB2GAKERBB4 | |
| SCHEMBL5067560 | 0.87 | EGFR (0.53) | EGFRERBB2GAK | |
| SCHEMBL5061534 | 0.86 | EGFR (0.56) | EGFRERBB2GAK | |
| SCHEMBL5061179 | 0.86 | EGFR (0.60) | EGFRERBB2GAKERBB3ERBB4 | |
| SCHEMBL5065393 | 0.85 | EGFR (0.55) | EGFRERBB2GAK | |
| SCHEMBL5064147 | 0.85 | EGFR (0.55) | EGFRERBB2GAK | |
| SCHEMBL5069008 | 0.84 | EGFR (0.67) | EGFRERBB2ERBB3ERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269238-A1 | Thiazolopyrimidine Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-30 | — | — | US | disclosed |
| US-20080269238-A1 | Thiazolopyrimidine Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-30 | — | — | US | disclosed |
| US-20080269238-A1 | Thiazolopyrimidine Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-30 | — | — | US | disclosed |
| EP-1731523-A1 | THIAZOLOPYRIMIDINE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2006-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269238-A1 | Thiazolopyrimidine Derivative | FGFR3, FGFR1, ERBB3 | EGFR 28/4885ERBB2 8/4885GAK 1781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.